MAINZ, Germany, December 8, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a digital press conference on Wednesday, December 8, 2021, to present the results from initial laboratory studies which started about two weeks ago. The studies aimed to investigate the effects of the Omicron variant on COVID-19 vaccine-induced immune responses. The press conference will solely be held in a virtual format and will be conducted in English.
International digital press conference at 3.00 pm CET / 9.00 am ET
Please register here.
The conference can be streamed. Interested journalists may dial in 10 to 15 minutes before the conference starts. They will be able to submit questions via an online tool.There will be no access for journalists on-site.
Participants may also digitally access the press conference on https://biontech.de/ under “Events & Presentations” in the Investor & Media section of the website. A recording of the press conference as well as the presentation will be available under the section “Past Events” on the same day.
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer.
For more information, please visit www.BioNTech.de
+49 (0)6131 9084 1513
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.